Jan Pinkas
Direttore Tecnico/Scientifico/R&S presso PYXIS ONCOLOGY, INC.
Posizioni attive di Jan Pinkas
Società | Posizione | Inizio | Fine |
---|---|---|---|
PYXIS ONCOLOGY, INC. | Direttore Tecnico/Scientifico/R&S | 12/04/2022 | - |
Corporate Officer/Principal | 01/08/2021 | 12/04/2022 |
Storia della carriera di Jan Pinkas
Precedenti posizioni note di Jan Pinkas
Società | Posizione | Inizio | Fine |
---|---|---|---|
IMMUNOGEN, INC. | Corporate Officer/Principal | - | - |
MAGENTA THERAPEUTICS | Corporate Officer/Principal | - | - |
Formazione di Jan Pinkas
University of Massachusetts | Doctorate Degree |
The Johns Hopkins University | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 6 |
Posizioni
Corporate Officer/Principal | 3 |
Chief Tech/Sci/R&D Officer | 1 |
Doctorate Degree | 1 |
Settori
Health Technology | 4 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
PYXIS ONCOLOGY, INC. | Health Technology |
Aziende private | 2 |
---|---|
Magenta Therapeutics, Inc.
Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
ImmunoGen, Inc.
ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
- Borsa valori
- Insiders
- Jan Pinkas
- Esperienza